Daiichi Sankyo Group has decided to close its Japanese research subsidiary, Asubio Pharma, based in Kobe, Japan, by the end of March 2018 as part of a reorganization of the company’s research and development (R&D) structure. Under this reorganization, Daiichi Sankyo plans to transfer Asubio Pharma R&D functions and employees to other Daiichi Sankyo companies in Japan.

Asubio Pharma has approximately 150 employees and mainly focuses on psychiatric and neurological diseases, immune and inflammatory diseases, and regenerative medicine, conducting research based on its position as a drug discovery venture within Daiichi Sankyo.

Source: Daichi Sankyo Group